Surmodics, Inc. (SRDX)
Automate Your Wheel Strategy on SRDX
With Tiblio's Option Bot, you can configure your own wheel strategy including SRDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SRDX
- Rev/Share 8.5148
- Book/Share 7.7214
- PB 3.8244
- Debt/Equity 0.0
- CurrentRatio 5.1432
- ROIC -0.1139
- MktCap 422258329.0
- FreeCF/Share -0.5212
- PFCF -56.7399
- PE -21.2269
- Debt/Assets 0.0
- DivYield 0
- ROE -0.1731
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | SRDX | Lake Street | Hold | Buy | -- | $43 | March 7, 2025 |
News
Why Is SurModics (SRDX) Up 6% Since Last Earnings Report?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?
Read More
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Despite the strength in Pounce thrombectomy device platforms and strong IVD product sales, Surmodics' second-quarter fiscal 2025 results show weak performance.
Read More
SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Negative
SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.07 per share a year ago.
Read More
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance
Published: April 30, 2025 by: Business Wire
Sentiment: Neutral
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon (.
Read More
Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon
Published: April 22, 2025 by: Business Wire
Sentiment: Neutral
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publication of the TRANSCEND clinical trial, a global randomized study demonstrating the SurVeil™ drug-coated balloon (DCB) is non-inferior to the IN.PACT™ Admiral™ DCB for safety and efficacy in patients with femoropopliteal arterial disease while using a substantially lower drug dose. The findings were.
Read More
SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Surmodics launches the Pounce XL Thrombectomy System, aiming to enhance clot removal efficiency, improve patient outcomes, and expand its portfolio of vascular interventions.
Read More
About Surmodics, Inc. (SRDX)
- IPO Date 1998-03-04
- Website https://www.surmodics.com
- Industry Medical - Devices
- CEO Mr. Gary R. Maharaj
- Employees 389